Company intelligence / Profile preview

Olfactive Biosolutions

Mountain View, California, United Statesolfactive.bio ↗

Ownership: Private
Development stage: Preclinical

Overview

The company has developed proprietary formulations of food molecules that can activate ectopic receptors to induce GLP-1 and GIP secretion for weight loss and blood sugar control, as well as formulations for blood pressure regulation. Their Pivit/Protenx products are scheduled for consumer launch in 2025.

Therapeutic areas: Metabolic DisordersEndocrinologyCardiovascular
Modalities: Food moleculesnatural ingredients
Industry: Food & Nutrition

Drug pipeline

1 asset

Pivit

Pre-clinical

Indications: Obesity, Type 2 diabetes

Partnerships

In talks with multinational food companies

Beyond the preview

Go deeper on Olfactive Biosolutions.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Olfactive Biosolutions.

Explore the full profile